Search

everythinglearnresearchcommunity

for

Search:↓

A 24-year-old shared their hair loss journey, switching from a 3-in-1 medication (finasteride, minoxidil, biotin) to a stronger 4-in-1 treatment (finasteride, dutasteride, minoxidil, biotin) with no side effects and noticeable hair growth. The user also discussed using hair dye cautiously to enhance the appearance of vellus hairs.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

The conversation discusses the use of TRT, dutasteride, minoxidil, and potentially RU58841 for hair loss. Concerns about the risk of developing Cutis verticis gyrata with minoxidil and TRT are raised.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

A 22-year-old male is concerned about hair loss and questions the effectiveness of prescribed "Merz special" and "Revalid" products, which lack finasteride or minoxidil. Users suggest seeking a different doctor for finasteride and minoxidil treatments.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

A 33-year-old experienced significant hair loss after a depressive episode and taking paroxetine, possibly due to telogen effluvium or androgenic alopecia. Suggestions included reducing alcohol, considering finasteride and minoxidil, and consulting a doctor about antidepressant side effects.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses hair loss treatments, specifically mentioning Spiro, Min, Fin, and RU. It highlights that Spiro is generally for women and can affect men's hormonal balance.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

A user experienced sleep paralysis after starting finasteride and is seeking others' experiences. Another user suggests finasteride might affect neurosteroids, potentially altering sleep patterns.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

The conversation is about someone using Dutasteride, oral Minoxidil, and Tretinoin for hair loss, and they also stopped antipsychotics and treated an H. pylori infection. They feel there has been progress in their hair growth over two months.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The conversation discusses using topical melatonin for diffuse thinning and mentions treatments like Minoxidil, finasteride, and RU58841. The user is seeking advice on whether melatonin could help with their condition.

Melatonin is being considered as a potential treatment for androgenic alopecia, with some users discussing its effects and combining it with other treatments like minoxidil and finasteride. Concerns about melatonin's impact on hormones and side effects from other treatments like ketoconazole were also discussed.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Asian dermatologists are more open to prescribing finasteride, while in some regions, medications like finasteride and minoxidil can be obtained without a prescription. In Europe, particularly France, there are stricter regulations requiring patients to acknowledge potential side effects, but many people find ways to obtain these treatments through various means.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A 21-year-old experiencing hair loss and depression is planning to start finasteride treatment and is asking for others' experiences. Another user responds positively, stating that finasteride has helped alleviate their depression caused by hair loss.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.